Miniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technologybroad
MiRA · Horizon Europe grant · 2024-05-01–2026-08-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
Acute lung failure (ALF) is the third leading cause of death globally and is characterised by severe respiratory impairment. When non-invasive ventilation (NIV) fails, the treatment escalates to invasive mechanical ventilation (IMV) - the current standard of care for ALF. IMV is highly invasive, with a high risk of complications and an avg. in-hospital mortality rate of 35%, costing thousands of euros per patient. Hospitals have signalled an unmet need for safe and adequate alternatives to IMV in ALF. HBOX Therapies GmbH is bringing MiRA (Miniaturised Respiratory Assist) to market: a disruptive and innovative hyperoxygenation therapy that combines unrivalled blood oxygenation and CO2 removal to treat ALF patients, while they are awake. Such a breakthrough therapy has the potential to be the first treatment option for ALF patients who fail NIV. MiRA therapy has an outstanding cost-effectiveness and improved patient outcomes by avoiding or limiting the need for IMV and further respiratory deterioration in these patients. The growing incidence & prevalence of respiratory diseases causing ALF suggests that there are up to 6 million ALF patients who could benefit from MiRA every year, representing a market potential of €10.4 B/year. Behind MiRA, there is our extracorporeal hyperbaric blood oxygenation (HBOX) technology - 2 patents protect the technology and the approach. HBOX has been validated in animal trials (TRL 5) and we now need to: i) finalise the integrated system for improved safety & efficacy, ii) complete clinical studies, and iii) obtain MDR/CE certification for the MiRA medical device to commence commercialisation. We expect the results of the MiRA project to accelerate the market entry of HBOX and to serve as a platform technology for additional clinical applications in the future. The EIC support will be key for our company to establish itself as a leading company in the respiratory industry.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| HBOX THERAPIES GMBH | DE | coordinator | €2,499,999 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.